Why do some people experience no pain after stimuli/injuries that lead to severe pain in others? Moreover, why are some people developing chronic disabling pain after minor injuries while others are pain free after major multi-trauma? These questions are of major interest to patients, clinicians, and to health providers. Experienced clinicians have long acknowledged the huge interindividual variation in pain sensitivity. However, it is poorly known how differences in pain sensitivity may influence diagnosis, as well as the course of illness, and the effect of treatment.
results similar to findings by Mogil et al. in rodents [6] . These studies indicate that genes may be identified that increase risks for acute pain and for chronification of acute pain.
The importance of pain sensitivity for pain as a symptom of serious illness.
This was recently shown by Granot et al. in a study of painful versus painless cardiac ischemia [7] . In persons hospitalized with cardiac ischemia, pain sensitivity differed between those presenting with pain as a main symptom and those presenting with other symptoms. Those who were sensitive to pain were more likely to present with painful ischemia, and thus they were most likely to receive an early correct diagnosis and treatment [7] . For specific diagnosis associated with pain, e.g., rheumatoid arthritis, the underlying pain sensitivity may explain the discrepancy between laboratory signs of illness severity and pain. Most importantly, underlying differences in pain sensitivity may explain why only a small number of patients with nerve injuries go on to develop chronic pain.
One special finding in both animal and human genetics is the lack of correlation between candidate genes and different pain models. Since genes may regulate peripheral pain transducers, neuronal conduction, general regulatory mechanisms of neuronal activity, as well as the immune system's involvement in plasticity of the pain regulatory systems, it is no surprise that both genes that regulate pain sensitivity in general as well as genes that regulate sensitivity to specific stimuli have been identified.
As shown most elegantly by Waxman and colleagues, single polymorphisms in one gene coding for a sodium channel (Na v 1.7) can give diverse phenotypes, ranging from insensitivity to pain to extremely severe pain syndromes [8] . These findings give hope that specific sodium-channels blockers may be developed for human use, for specific treatment of pathologic pain without interfering with other functions.
Analgesic efficacy has been linked with the human catechol-O-methyltransferase (COMT) gene [9, 10] , the OPRM1 gene [11] , the CYP2D6 gene [12] , the MC1R gene [1] and the gene encoding cyclooxygenase-2 (COX-2) gene [13] . Again, except for CYP2D6, contradictory findings are frequent. The lack of clean phenotypes and lack of adequately sized studies have been limiting factors for progress.
Genes associated with the chronification of pain have recently been identified [14] . CACNG2 encodes for a protein involved in the transport of glutamatergic receptors as well as possibly being a Ca channel subunit [14] . Human CACNG2 polymorphisms were associated with chronic pain in a cohort of breast cancer patients [14] .
Most interestingly, Costigan et al. found that a common polymorphism coding for a potassium channel subunit involved in neuronal excitability was associated with higher pain scores in five of six independent patient cohorts [15] . This channel is constitutively expressed in sensory neurons and markedly downregulated following nerve injury, indicating a specific role in chronification after injuries. Now, as technology makes genome-wide association studies (GWAS) possible, mapping more than one million single-nucleotide polymorphisms (SNPs) from each subject can be done, and new candidate genes and new mechanisms may be found. However, the crucial need for adequately sized studies becomes even more important [16] . For GWAS studies, 1000-3000 carefully phenotyped subjects are needed to gain adequate power [17] . This means that large multicenter trials may be the only way forward.
Before we start doing this, one lesson from the studies in redheads should be brought forward. As pointed out by Andresen et al. [3] , slightly different test protocols may explain the divergent findings between Liam et al. [2] and the current study by Andresen et al. [3] . Low rates of skin heating (<0.5 • C/s) activate mainly C-fibers whereas high rates (>0.9 • C/s) predominantly activates A␦-fibers. This underscores the fact that both for experimental and clinical outcomes, lack of reproducible and well-characterized phenotypes limits progress in this field of research. The finding of reduced sensitivity in redheads for pinprick hyperalgesia reported in this issue of the Scandinavian Journal of Pain by Lars ArendtNielsen's group is interesting [3] . If replicated, this may indicate a contribution of the melanocortin receptor gene to pain plasticity.
